News|Articles|March 15, 2020
- Pharmaceutical Technology-03-15-2020
- Volume 2020 eBook
- Issue 1
Inside FDA’s New Gene and Cell Therapy Guidances
Author(s)Agnes Shanley
In January 2020, the agency finalized six clinical development and manufacturing guidance documents and drafted new guidance on what would qualify new gene therapies as orphan drugs.
Advertisement
Since 2017, FDA has approved four gene therapies, and regulators expect the number of gene and cell therapies under development to increase dramatically.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook, March 2020
March 2020
Pages: 6–9
Citation
When referring to this article, please cite it as A. Shanley, “Inside FDA’s New Gene and Cell Therapy Guidances," Pharmaceutical Technology Regulatory Sourcebook eBook (March 2020).
Articles in this issue
over 5 years ago
Resources, Guidelines, and Guidance Documentsover 5 years ago
Regulatory and Standard Setting Organizationsover 5 years ago
A ‘New Normal’ for Quality?over 5 years ago
Monograph Development: Why and When to Participate (eBook)over 5 years ago
A Practical Approach to Pharmacopoeia Compliance (eBook)over 5 years ago
ALCOA+ and Data IntegrityNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Sustainability and Stability in Excipients
2
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
3
AI and Human Collaboration Essential for Bio/pharma Innovation
4
Why Sound Science Is Pharma's Best Defense Against Regulatory Shifts
5
